Education
About Us
Working with TipRanks
Follow Us
Jasper Therapeutics (JSPR)
NASDAQ:JSPR
JSPR Analyst Ratings
Strong Buy
11 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
JSPR Stock 12 Month Forecast
Average Price Target
$60.38
▲(1147.52% Upside)
| Highest Price Target$80.00 | Average Price Target$60.38 | Lowest Price Target$38.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
Reiterated
03/11/25
TD Cowen
Reiterated
03/03/25
Oppenheimer
Reiterated
03/03/25
Cantor Fitzgerald
Reiterated
03/03/25
JMP Securities
Reiterated
03/03/25
William Blair
Reiterated
03/03/25
BTIG
Reiterated
03/02/25
Stifel Nicolaus
Reiterated
03/02/25
BMO Capital
Initiated
02/27/25
RBC Capital
Reiterated
02/27/25
UBS
$38
Buy
685.12%
Upside
Initiated
02/13/25
Jasper Therapeutics (JSPR) Gets a Buy from UBSwe are initiating coverage of the CSU space with Buy ratings for Jasper Therapeutics (JSPR; $38 PT) and Celldex (CLDX; $44 PT)
Evercore ISI
$65
Buy
1242.98%
Upside
Reiterated
12/24/24
We shared this last week in our ’25 outlook and accompanying webinar, but given the proximity to data and importance to JSPR – we want to send a separate note to make sure it didn’t get missed.
Capital One Financial
$55
Buy
1036.36%
Upside
Assigned
10/23/24
Buy Rating on Jasper Therapeutics Driven by Promising Clinical Developments and Strategic Advancements
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
Reiterated
03/11/25
TD Cowen
Reiterated
03/03/25
Oppenheimer
Reiterated
03/03/25
Cantor Fitzgerald
Reiterated
03/03/25
JMP Securities
Reiterated
03/03/25
William Blair
Reiterated
03/03/25
BTIG
Reiterated
03/02/25
Stifel Nicolaus
Reiterated
03/02/25
BMO Capital
Initiated
02/27/25
RBC Capital
Reiterated
02/27/25
UBS
$38
Buy
685.12%
Upside
Initiated
02/13/25
Jasper Therapeutics (JSPR) Gets a Buy from UBSwe are initiating coverage of the CSU space with Buy ratings for Jasper Therapeutics (JSPR; $38 PT) and Celldex (CLDX; $44 PT)
Evercore ISI
$65
Buy
1242.98%
Upside
Reiterated
12/24/24
We shared this last week in our ’25 outlook and accompanying webinar, but given the proximity to data and importance to JSPR – we want to send a separate note to make sure it didn’t get missed.
Capital One Financial
$55
Buy
1036.36%
Upside
Assigned
10/23/24
Buy Rating on Jasper Therapeutics Driven by Promising Clinical Developments and Strategic Advancements
JSPR Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
22
20
17
17
17
Buy
3
2
1
2
5
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
25
22
18
19
22
Each month's total comprises the sum of three months' worth of ratings.
JSPR Financial Forecast
JSPR Stock Forecast FAQ
What is JSPR’s average 12-month price target, according to analysts?
Based on analyst ratings, Jasper Therapeutics’s 12-month average price target is $60.38.
What is JSPR’s upside potential, based on the analysts’ average price target?
Jasper Therapeutics has 1147.52% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is JSPR a Buy, Sell or Hold?
Jasper Therapeutics has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.
What is Jasper Therapeutics’s price target?
The average price target for Jasper Therapeutics is $60.38. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $80.00 ,the lowest forecast is $38.00. The average price target represents 1147.52% Increase from the current price of $4.84.
The highest analyst price target is $80.00 ,the lowest forecast is $38.00. The average price target represents 1147.52% Increase from the current price of $4.84.
What do analysts say about Jasper Therapeutics?
Jasper Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
How can I buy shares of JSPR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.